Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01079832 · ClinicalTrials.gov registry record · Phase 2
Stereotactic Radiosurgery Using CyberKnife in Treating Women With Advanced or Recurrent Gynecological Malignancies
A Phase 2 study of Fallopian Tube Cancer and Recurrent Endometrial Carcinoma, sponsored by Case Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT01079832 is a Phase 2 study of Fallopian Tube Cancer and Recurrent Endometrial Carcinoma that has completed, run by Case Comprehensive Cancer Center. The registered enrollment target is 50 participants, below the 255-participant average among 85 other Fallopian Tube Cancer trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01079832, a Phase 2 study of Fallopian Tube Cancer and Recurrent Endometrial Carcinoma, has completed, sponsored by Case Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
RATIONALE: Stereotactic radiosurgery can send x-rays directly to the tumor and cause less damage to normal tissue. PURPOSE: This clinical trial studies stereotactic radiosurgery using CyberKnife works in treating women with advanced or recurrent gynecological malignancies.
Conditions Studied
Interventions
- PROCEDURE quality-of-life assessment
- RADIATION stereotactic radiosurgery
Study Locations (1)
Ohio
- Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2009-05 |
| Est. Completion | 2012-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01079832
The ClinicalTrials.gov registry entry for NCT01079832 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 255-participant average among 85 other Fallopian Tube Cancer trials with a reported enrollment target (80% lower). The listed sponsor is Case Comprehensive Cancer Center, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Fallopian Tube Cancer appearing as the primary indexed condition, and to 2 interventions - of which quality-of-life assessment is the first listed.
NCT01079832 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT01079832 about?
NCT01079832 is a clinical study titled "Stereotactic Radiosurgery Using CyberKnife in Treating Women With Advanced or Recurrent Gynecological Malignancies". RATIONALE: Stereotactic radiosurgery can send x-rays directly to the tumor and cause less damage to normal tissue. PURPOSE: This clinical trial studies stereotactic radiosurgery using CyberKnife works in treating women with advanced or recurrent gynecological malignancies.
What is the current status of trial NCT01079832?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2009-05. Estimated completion is 2012-05.
What conditions does trial NCT01079832 study?
This clinical trial studies the following conditions: Fallopian Tube Cancer, Recurrent Endometrial Carcinoma, Recurrent Ovarian Epithelial Cancer, Ovarian Sarcoma, Recurrent Uterine Sarcoma.
What interventions are being tested in trial NCT01079832?
The interventions under investigation include: quality-of-life assessment (PROCEDURE), stereotactic radiosurgery (RADIATION).
Who is sponsoring clinical trial NCT01079832?
This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01079832 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Fallopian Tube Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
RECRUITING · Phase 2
-
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
RECRUITING · Phase 2
-
An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib
RECRUITING · Phase 2
-
A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies
RECRUITING · Phase 2
-
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
RECRUITING · Phase 2
-
CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.